Scientists have discovered that certain wound-healing peptides could help reduce harmful bacterial buildup in the lungs of people with cystic fibrosis, a genetic disease that causes long-term respiratory infections.
The research, led by the University of Geneva (UNIGE), suggests that these peptides may help restore the natural protective barrier in airway cells and make it harder for bacteria to stick and grow. The findings were published in Communications Biology.
What the researchers found
Cystic fibrosis damages the airways, making patients more vulnerable to chronic bacterial infections. According to the study, this happens because a protein called connexin 43 becomes abnormally active in the lungs.
Normally, connexin 43 helps cells communicate and only becomes active during tissue repair. But in cystic fibrosis, it stays active for too long. This disrupts how airway cells are organised and creates “anchor points” where bacteria can attach.
Using 3D models of human lung cells, the researchers observed that this abnormal activity leads to disordered tissue structure and increased bacterial adhesion on the surface of the airways.
Peptides help restore airway protection
The team then tested a solution by blocking the activity of connexin 43. When they did this, the cells regained their normal structure and organisation, reducing the formation of bacterial “anchor points”.
They also used mimetic peptides—short synthetic molecules already being tested in other medical fields such as dermatology and cancer treatment. These peptides significantly reduced bacterial colonisation in the airway cell models.
Researchers say this suggests the peptides could help strengthen the lungs’ natural defences and limit the risk of serious infections in cystic fibrosis patients.
Why this matters
Despite improvements in treatment, lung infections remain one of the most serious complications for people with cystic fibrosis. Finding new ways to stop bacteria from attaching to airway surfaces could make a major difference in long-term care.
The study’s authors say their findings highlight a deeper biological mechanism behind infection risk and open the door to potential new therapies that target how airway cells communicate and organise themselves.
While more research is needed before any clinical use in cystic fibrosis patients, the results offer a promising direction for future treatment strategies.